Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pulmatrix, Inc. on July 19, 2019. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the listing notice.
- Stock Price Deficiency: The closing bid price of the Company's common stock remained below $1.00 per share for 30 consecutive business days (June 6, 2019, through July 18, 2019).
Material Changes
The material event reported is the failure to meet the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). This deficiency has resulted in a formal notice of potential delisting.
Outlook, Risks, and Contingencies
Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending January 15, 2020, to regain compliance.
Remediation Requirements: To cure the deficiency, the Company must maintain a minimum closing bid price of $1.00 for at least ten consecutive days during the compliance period.
Secondary Compliance Option: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period. Qualification for this extension requires meeting all other initial listing standards (excluding bid price) and may necessitate a reverse stock split.
Delisting Risk: If the Company cannot cure the deficiency or is deemed ineligible for an extension, Nasdaq will issue a notice that the common stock will be subject to delisting.
Current Status: The notice has no immediate impact on trading; the stock will continue to be listed and traded on The Nasdaq Capital Market pending compliance.
Investor Verification Checklist
- Verify the current closing bid price of Pulmatrix common stock (PULM) to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split as a potential cure mechanism.
- Review subsequent filings to confirm if the Company meets the ten-day consecutive trading requirement before January 15, 2020.
- Check for any updates on the Company's ability to meet other Nasdaq initial listing standards if a second compliance period is required.